A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to '18 Years With Chronic Kidney Disease on Dialysis
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Lanthanum carbonate (Primary) ; Calcium carbonate
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Shire
- 02 Apr 2019 Status changed from active, no longer recruiting to completed.
- 10 Feb 2019 This trial has been completed in Hungary.
- 19 Dec 2018 This trial has been completed in Czech Republic.